Detalles de la búsqueda
1.
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
PLoS Med;
21(3): e1004360, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38502656
2.
Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
Nature;
561(7724): 479-484, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30258136
3.
Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120.
J Infect Dis;
2023 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37795976
4.
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.
J Infect Dis;
226(2): 246-257, 2022 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35758878
5.
Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1.
J Virol;
93(7)2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30700599
6.
Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens.
J Immunol;
201(4): 1315-1326, 2018 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30006374
7.
Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.
Nature;
505(7484): 502-8, 2014 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24352234
8.
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.
J Infect Dis;
217(8): 1280-1288, 2018 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-29325070
9.
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
J Virol;
91(24)2017 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29021394
10.
HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques.
J Virol;
91(21)2017 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28794027
11.
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
PLoS Med;
14(11): e1002435, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29136037
12.
Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1.
J Virol;
89(19): 9952-61, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26202232
13.
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
Lancet HIV;
11(5): e285-e299, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38692824
14.
Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants.
PLOS Glob Public Health;
3(6): e0002037, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37289667
15.
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
Vaccine;
41(42): 6309-6317, 2023 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37679276
16.
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
Lancet HIV;
10(10): e653-e662, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37802566
17.
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
Nat Commun;
14(1): 8299, 2023 Dec 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38097552
18.
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition.
EBioMedicine;
93: 104590, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37300931
19.
Lower SARS-CoV-2-specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19.
JCI Insight;
7(21)2022 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36136590
20.
Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children.
J Acquir Immune Defic Syndr;
91(2): 182-188, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36094485